Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
JAK3 (Janus Kinase 3)
i
Other names:
JAK3, Janus Kinase 3, Tyrosine-Protein Kinase JAK3, Leukocyte Janus Kinase, JAK-3, L-JAK, Janus Kinase 3 (A Protein Tyrosine Kinase Leukocyte), JAK3_HUMAN, JAKL, LJAK
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3718
Related tests:
‹
Guardant360® CDx (54)
TruSeq®Amplicon - Cancer Panel (5)
Guardant360 TissueNext™ (2)
AVENIO Tumor Tissue Expanded Kit
AVENIO ctDNA Expanded Kit
Archer® VariantPlex® Myeloid panel
Archer® VariantPlex® Solid Tumor Kit
Archer™ VARIANTPlex™ Pan Solid Tumor panel
FusionPlex™ Pan-Heme panel
Labcorp® Plasma Complete™
LiquidHALLMARK®
NexCourse®
Northstar Select™
NovoFocus™ CRC 2.0
NovoFocus™ NSCLC 2.0 Test
OncoGuide™ NCC Oncopanel System
OncoSTRAT&GO
Oncomine Focus Assay
OptiSeq™ Pan-Cancer Gene Panel
StrataNGS™ Test
SureSeq™ Pan-Myeloid Panel
TruSight Myeloid Sequencing Panel
TruSight Tumor 170 Assay
VarMap™ Pan-Cancer NGS Panel
oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel
Guardant360® CDx (54)
TruSeq®Amplicon - Cancer Panel (5)
Guardant360 TissueNext™ (2)
AVENIO Tumor Tissue Expanded Kit
AVENIO ctDNA Expanded Kit
Archer® VariantPlex® Myeloid panel
Archer® VariantPlex® Solid Tumor Kit
Archer™ VARIANTPlex™ Pan Solid Tumor panel
FusionPlex™ Pan-Heme panel
Labcorp® Plasma Complete™
LiquidHALLMARK®
NexCourse®
Northstar Select™
NovoFocus™ CRC 2.0
NovoFocus™ NSCLC 2.0 Test
OncoGuide™ NCC Oncopanel System
OncoSTRAT&GO
Oncomine Focus Assay
OptiSeq™ Pan-Cancer Gene Panel
StrataNGS™ Test
SureSeq™ Pan-Myeloid Panel
TruSight Myeloid Sequencing Panel
TruSight Tumor 170 Assay
VarMap™ Pan-Cancer NGS Panel
oncoReveal™ Multi-Cancer with CNV & RNA Fusion Panel
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
JAK3 mutation
Non Small Cell Lung Cancer
JAK3 mutation
Non Small Cell Lung Cancer
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
JAK3 amplification
Non Small Cell Lung Cancer
JAK3 amplification
Non Small Cell Lung Cancer
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
JAK3 mutation
Prolymphocytic Leukemia
JAK3 mutation
Prolymphocytic Leukemia
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
venetoclax + ruxolitinib
Sensitive
:
C3
venetoclax + ruxolitinib
Sensitive: C3 – Early Trials
venetoclax + ruxolitinib
Sensitive
:
C3
JAK3 mutation
T Acute Lymphoblastic Leukemia
JAK3 mutation
T Acute Lymphoblastic Leukemia
tofacitinib
Resistant: C4 – Case Studies
tofacitinib
Resistant
:
C4
tofacitinib
Resistant: C4 – Case Studies
tofacitinib
Resistant
:
C4
JAK3 M511I
T Acute Lymphoblastic Leukemia
JAK3 M511I
T Acute Lymphoblastic Leukemia
tofacitinib XR
Sensitive: D – Preclinical
tofacitinib XR
Sensitive
:
D
tofacitinib XR
Sensitive: D – Preclinical
tofacitinib XR
Sensitive
:
D
JAK3 M511I
T Acute Lymphoblastic Leukemia
JAK3 M511I
T Acute Lymphoblastic Leukemia
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
ruxolitinib
Sensitive: D – Preclinical
ruxolitinib
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.